MedTrace Logo

Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis

NCT00997438 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2017-01-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn about how the antioxidant, lipoic acid, works in the body and how it may help in the management of relapsing remitting and secondary progressive multiple sclerosis. This study will compare how subject's and healthy volunteers bodies absorb and break down the supplement. This information may help in developing new therapies.

Conditions

Interventions

DIETARY_SUPPLEMENT

Lipoic Acid

300 mg Lipoic acid tablets from Vital Nutrients

Sponsors & Collaborators

  • Oregon Health and Science University

    collaborator OTHER

  • Portland VA Medical Center

    lead FED

Principal Investigators

  • Daniel Carr, Ph.D · Portland VA Medical Center and Oregon Health & Science University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00997438 on ClinicalTrials.gov